Try our Advanced Search for more refined results
Life Sciences - July, 2014
303 articles
- AbbVie Investor Says Brass Exposed Co. To Off-Label Claims
- OPINION: Lawyers Should Think In Terms Of Big Data
- Jones Day Video Sanction Shows Attys Can Go Too Far
- FDA Lab Test Oversight Will Touch Off Industry Tug-Of-War
- 6th Circ. Rules Breast Implants Are Tissue Expanders
- Deals Rumor Mill: Harvard Drug, Canaan, Alibaba
- Blackstone-Backed Drug Tech Co. Raises $823M In IPO
- 1st Circ. Grills Attys On Nexium Pay-For-Delay Class Cert.
- Swedish Drug Co. Meda Pays $3.1B For Rottapharm
- Bristol-Myers Must Face Out-Of-State Plavix Claims In Calif.
- 4 Goals, 4 Years And 1 Budget: The FDA's Ambitious Plan
- J&J Unit Recalls Hysterectomy Device Over Cancer Fears
- Jones Day Atty Sanctioned For Discovery Abuse In Abbott Row
- Bankrupt Natrol Gets Nod For Cerberus Settlement
- Pa. Medical Suppliers Can't Duck Antitrust Class Action
- Cephalon Can't Fight IP Battle In FTC Pay-For-Delay Suit
- Boehringer Sues Amneal To Block Generic Aggrenox
- China Trumpets Advancements In IP Protection Regime
- AstraZeneca Flaunts Stand-Alone Prospects With $2.1B Deal
- Pfizer Shells Out $635M To Beef Up Vaccines Biz
- Fed. Circ. And USPTO Diverge On Lead Compound Analysis
- Death Rattle For Unfinished Business Claims?
- Boston Scientific Wins First Pelvic Mesh Injury Trial
- NJ High Court Cases Could Limit Whistleblower Protection
- 2nd Circ. Upholds $2.5M False Ad Award To Merck
- And Now A Word From The Panel: Top 10 Venue Arguments
- FedEx Denies It Illegally Distributed Generic Valium, Xanax
- FDA Faults Impax Quality In Latest Blow To Rytary Approval
- Endo, Watson Seek Dismissal Of Lidoderm Pay-For-Delay Suits
- Abbott Holds Onto $84M Win Against Lloyd's In Ill.
- Merck Won't Join Inversion Craze, CEO Says
- House Agrees To Prescription Drug Enforcement Overhaul
- Pfizer Unit Can't End Skelaxin Pay-For-Delay Row In Pa.
- Lagging Pfizer Revenue Reinvigorates M&A Speculation
- Dealmakers Q&A: Morris Manning's David Calhoun
- Classic Issues Face Cutting-Edge Neurofeedback Practices
- Novartis Ducks Non-Negligence Claims In Zometa Suits
- FDA's Biggest New Policies Of 2014: Midyear Report
- Vascular Solutions Settles Ex-Sales Rep's FCA Suit
- Drug Discount Deal Won't Trigger Kickback Penalties: OIG
- Docs' Groups Ask CMS For Preview Of Sunshine Data Context
- IRS Releases Final Rules On Branded Prescription Drug Fee
- GSK, Teva Fight FTC Bid To Join Lamictal Args In 3rd Circ.
- Sens. Press FDA For Plan On Antibiotic Use In Farm Animals
- BakerHostetler Snags Ex-Foley & Lardner Trademark Pro
- Del Monte Sued By Vitamin Maker Over 'Nature Made' Mark
- CTCA Sues Avax For $5.8M Over Cancer Vaccine Promise
- Deals Rumor Mill: CVC, Fox, Danone
- Norton Rose Faces Renewed DQ Bid In Pamlab Suit
- Dealmakers Q&A: Burns & Levinson's Josef Volman
- EU Rule Sets Higher Standard For Medical Devices
- Don't Get Carried Away By The Inversion Craze
- What The Supreme Court Said About Patents This Term
- Endo Can't Stop Settlement Order In Frova Patent Row
- Justices Should Back Off Patent Eligibility, Michel Says
- DLA Piper Nabs Hogan Lovells Life Sciences M&A Pro
- Retroactive Inversion Ban May Kill Pending Deals
- Judge Rinses Claims From Mouthwash False Ad Row
- 1st Circ. Nexium Case May Ripple Beyond Pharma
- FDA Limits Multiproduct Comparisons In 510(k) Submissions
- Judge Asks If Dreier Fall Busts Browne Arbitration Clause
- Herbalife, Allergan Lead To Questions Over Ackman Strategy
- Calif. Buyers Ask 1st Circ. To Revive Lexapro Marketing Suit
- GSK Investigating Alleged Misconduct By Former Syria Ops
- Calif. Judge Won't Sever Walgreen Homeopathic Meds Row
- Ireland Defends Itself After Obama Blasts Inversion Surge
- Litigator's Perspective: 5 Tips On Arbitration Provisions
- Stryker Can't Ax Counterclaims In Customer Sabotage Row
- Biosimilars Clarity Coming As FDA Eyes Sandoz Application
- FDA Gives Equivalent Rating To Perrigo's Testosterone Gel
- Pa. Risperdal Judge Won't Change Mind On Nixing Punitives
- Walgreen Wins Dismissal In Pharmacy Buyout Suits
- 2nd Circ. Sides With FDA In Livestock Antibiotics Spat
- Janssen Hits Mylan With Generic Prezista Patent Suit
- Diet Drug Maker's Last-Ditch Suit Against FTC Dismissed
- House Reps. Press For Change After Ackman Allergan Bid
- Dechert Picks Up IP, Life Science Pro From Goodwin Procter
- 6 Years In, Why Haven't FRE 502(d) Orders Caught On?
- Gordon & Rees Nabs Weber Gallagher Product Liability Atty
- FDA Accepts First Biosimilar Application From Sandoz
- Valeant Files Another Complaint Over 'False' Allergan Info
- Prosecutions Loom Large In China's Food Regulatory Regime
- Amid M&A Uptick, Bidders Must Heed UK Code Changes
- Generic Drugs At 30: Fulfilling The Promise And Path Ahead
- 3rd Time's A Charm For Miss. AG's Plavix Remand Motion
- Rare Fed. Circ. Reversal Spurs Trial On Inequitable Conduct
- GNC Ducks Herbal Testosterone Supplement RICO Action
- Apotex Blocked From Continuing Generic Paxil Sales
- Bioplastics Sister Cos. Meredian, DaniMer Agree To Merge
- AIG Unit Can't Escape $3.75M Verdict In Ad Injury Case
- Nixon Peabody, Mintz Levin Blamed For Biotech's Downfall
- Government Seeks To Outsource Criminal Enforcement
- Trial-Ready In 180 Days: Prepare For SDNY's Rocket Docket
- Out-Of-State Accutane Users Shut Out Of Calif. Litigation
- No Deal In Stryker's Suit Over $3M Scheme, Judge Says
- Stalwart Firm Cementing Place As Megadeal Powerhouse
- GrayRobinson Forms Group To Target Medical Marijuana
- Shareholders Fight Hemispherx's Fee-Shifting In Del. Chancery
- $10M J&J Motrin Verdict Upheld By Pa. Appeals Court
- Insurer Sues 23andMe To Duck Coverage Of DNA Test Suits
- Stiefel Calls 11th Circ. Ruling On Duty To Disclose Confusing
- Activist Investor Ackman's Herbalife 'Deathblow' Backfires
- Deals Rumor Mill: WH Group, GlaxoSmithKline, Huarong
- Judge's Marriage Bars Other SDNY Judges From Hearing Suit
- Vitamin C Makers Tell 2nd Circ. To Uphold Chinese Law
- Vedder Price Snags Merck Patent Pro For NY Office
- German Insurer Can Continue To Fight $15M HIV Settlement
- The Promise And Problem Of Genomic Marketing
- Novus Wants Rival Sanctioned In Sex Enhancer Rip-Off Row
- Boston Scientific Wants Vaginal Mesh Expert Out Of MDL
- Braintree Says Suprep Case Doesn't Upend Drug Patent Law
- Deals Rumor Mill: Fox, Allergan, Elliott Management
- LA Sues Hospital For Spinal Implant Overbilling Scheme
- HHS Formalizes 340B Policy As Court Fight Continues
- Keep Norton Rose On Pamlab Unfair Comp Row, Judge Says
- Canada Blasts Lilly's $500M Patent Law Challenge
- Gilead Hits Lupin With Patent Suit Over HIV Drug Atripla
- Valeant Tells Regulators Allergan Is Misleading Investors
- Proskauer Can Point Finger At Accountant In J&J Fraud Suit
- Apotex 'Thumbing Its Nose' At Paxil Bar, Mylan Says
- FDA Warns Of Lethal Potential Of Caffeine Powder
- Steptoe Expands NY Office With Ex-Mayer Brown IP Litigator
- EPA May Threaten Reverse Distribution Of Pharmaceuticals
- FDA To Examine Teen Reactions To Drug Promos
- ITC Overstepped In Flipping ALJ Order, Fed. Circ. Says
- Taxation With Representation: Cravath, Simpson Thacher
- GOP Wary Of Attys' Influence On FDA Generics Labeling Rule
- FDA Urged To Add New Black Box Warning On J&J's Levaquin
- LBDS Admits Using Phony Docs In $25M Trade Secrets Suit
- Blackstone-Backed Catalent Aims For $935M IPO
- Medicare Eases Controversial Part D Prior Authorizations
- Mylan Faces $100M Tax Bill Over Drug Agreement With Forest
- 5 Insights From Pfizer Chief Litigation Counsel Michael Parini
- Pfizer Celebrex Suits Should Be Coordinated, Judge Hears
- AbbVie Seals $54B Shire Takeover In Major Inversion Deal
- Powerful Tools For Discovery And Litigation Strategy
- Growing Insistence Among Courts For Ascertainability
- Big Deals, Strong Economy To Keep M&A Cooking
- Corporate Inversions Show No Signs Of Slowing Down
- Kirkland Reps GTCR In $480M Thermo Fisher Carveout
- FedEx Indicted On Charges Of Aiding Illegal Online Pharmacies
- Megamerger Bids Become New Norm As Deal-Making Heats Up
- NJ Mass Torts Judge Bound For Appellate Division
- Deals Rumor Mill: Siemens, Shire, Murphy Oil
- FTC Looks To Join Lamictal Pay-For-Delay Oral Args
- FDA Fine-Tunes Informed Consent Rules
- NJ Judge Won't Disturb $11M Award In J&J Mesh Mass Tort
- PRISM Scatters Attorney-Client Privilege
- FDA Balks At Black Box Warnings On Testosterone Drugs
- $53B Allergan Bid Risks Collapse If No Deal In 2014
- FDA Slaps Concordia Pharmaceuticals Over ADHD Drug Promo
- Employers Directed To Disclose Birth Control Objections
- Dealmakers Q&A: Jenner & Block's Tom Stromberg
- Fighting 'Superbugs' With Next Generation Antibiotics
- OPINION: Let's Financially Reward Law Firm Diversity
- Icahn And Ackman Hug, Publicly End CNBC Feud
- Mylan Scores Block On GSK's Generic Paxil Deal
- FDA Revokes Approval For 7 Acetaminophen Painkillers
- 9th Circ. Affirms Intuitive Win In Investor Class Action
- Deals Rumor Mill: Microsoft, Blackstone, Sanofi
- Google Ad Policies Cloud FDA's Drug Promo Guidance
- Oscar Winner Defends Tweets In Suit Over Endorsement Deal
- Vitamin C Buyers Say AUO Ruling Backs Their Antitrust Case
- Bankrupt Natrol Inks Pact With Cerberus, Quells Trustee Bid
- Medicis Dodges Liability In Acne Drug Hair-Loss Suit
- Teva Says It Doesn't Belong In Pay-For-Delay MDL
- Crucial Predictive Coding Case Law: Progressive V. Delaney
- Calif. Drug Bill Would Frustrate Pharmacy Operations
- Dealmakers Q&A: Ballard Spahr's Craig Circosta
- Bristol-Myers Wants Fed. Circ.'s En Banc Review Of Patent
- 3 Key Facts From The EU's Latest Pay-For-Delay Case
- Iowa Court Offers Limited Boost To Generic-Drug Injury Suits
- Mutual Pharma Inks $9M Deal To Settle Pay-For-Delay Claims
- Bayer Lures Pfizer Atty To Head US Litigation Unit
- Drug Distributor, Pharmacy Settle Contract Suit For $1.65M
- OPINION: Advance Conflict Waivers Send Wrong Message
- FDA Rejects Ban On Controversial Vaginal Mesh Products
- FDA Rips Italian Drug Ingredient Co. For Deleted Test Data
- Actavis Sued Over Generic Morning Sickness Drug
- Ivy Realty Gets $64M For Sandoz's New Jersey HQ
- 8th Circ.'s 'Liberal Admission' Standard Stands Out
- 5th Circ. Frees Pfizer Unit, Others From Generic-Reglan Suit
- Ranbaxy Attacks Hyman Phelps' FDA Exclusivity Petition
- Fed. Circ. Remands Thermometer Patent Suit
- FDA Details Risk-Benefit Stance On 510(k) Device Approvals
- Cephalon Wins Dismissal Of Travelers' $22M Marketing Suit
- NCR Can't Collect Cleanup Costs From Coke, GSK: 6th Circ.
- 5 Tips For Crafting Multistate FCA Settlements
- Wyeth Defends Immunity Bid In Effexor Pay-For-Delay Case
- BigLaw Rips OIG On Medicare Exclusion Time Limits
- Allergan Lobs More Criticism Amid $53B Valeant Buyout Push
- Warner Chilcott To Pay $8M Over Generic Doryx Delay
- Travelers Denies Coverage For Med Co.'s $67M Settlements
- Octane Fitness Gives Medtrica, Steris Second Shot At Fees
- BIO, PhRMA Ask Fed. Circ. To Revisit Double-Patent Ruling
- Fresenius Sued By Cubicin Maker Over Generics Application
- Shire Signals Support For Landmark $53B AbbVie Merger
- Mylan Adds To Inversion Surge With $5.3B Abbott Deal
- Greater Clarity Comes To Nanotech, Courtesy Of The FDA
- Senators Demand Pricing Details On $1,000-Per-Pill Sovaldi
- Whistleblower Again Asks High Court To Mull Leave To Amend
- Novartis Escapes Punitive Damages In Zometa Suit
- US-China Investment Pact Talks May Spur Market Reform
- Wal-Mart Escapes FCA Suit Over Narcotic Prescriptions
- AbbVie Braces For Busy Week Before $51B Shire Bid Deadline
- Iowa High Court Spares Wyeth From Generics Injury Claims
- States May Be Moving To Expand The Federal Sunshine Law
- Covidien Shareholders Sue To Block $42.9B Medtronic Merger
- National Union Denies Coverage For Med Co.'s $100M Suit
- DOJ Scores $2B In FCA Settlements For 1st Half Of 2014
- Deals Rumor Mill: Airbus, WH Group, KKR
- Mass. Gov. Signs Law Reforming Compounding Regs
- Fla. High Court Says No Bright-Line Rule For Sublicensing
- Two Sectors Prove Key To M&A Upswing In 2014
- Pfizer Unit Wants End To Skelaxin Pay-For-Delay 'Odyssey'
- Dr. Reddy's Infringes Cancer Med Patents, Allos Says
- Paul Hastings Adds White Collar Partner From Kaye Scholer
- McGuireWoods Snags IP, Life Sciences Pro For DC Office
- Dealmakers Q&A: Dechert's Daniel O'Donnell
- Legal Forms And IP Rights: Yours, Mine, Ours Or Theirs?
- AbbVie Gets More Humira Patent Claims Invalidated
- FDA Calls Supplement Co.'s Facebook 'Likes' Endorsements
- Biomet Hip Suit Remanded On Distributor Liability Issue
- Thermo Fisher Can't Dodge Suit Over Cartel-Plagued Lab
- Inversion Surge Proves Allure Trumps Risk For Deal Makers
- Backlash Has White House Ready To Drop USPTO Pick
- EU Fines Servier, Others $583M Over Pay-For-Delay Deals
- FDA Clinical Trials Need More Flexibility, Lawmakers Say
- Ireland Posts Big M&A Numbers Amid Pharma, Inversion Deals
- Deals Rumor Mill: Quiron, Televisa, Green Street Advisors
- AbbVie Flouts UK Rules With Comments About Shire Investors
- Medicaid Act May Offer Cause Of Action Against Rate Cuts
- Zogenix Beats Mass. Dismissal Bid In Painkiller Row
- Cadence Sanctioned In Generic Drug Patent Dispute
- Rival Says J&J Unit Monopolizes Glucose Test Strip Market
- Roche, Helsinn Sue Dr. Reddy's Over Generic Aloxi
- Ranbaxy Pays $2.3M To Settle Generic Safety Suit
- Legal Trends And Troubles Involving Medical Marijuana
- Premier Law Firms Making Bank In Valeant-Allergan Battle
- 5 Insights From Home Depot GC Teresa Roseborough
- Hughes Hubbard Dodges Suit From Disgruntled Vioxx Plaintiff
- Guidant Can't Escape J&J's $22B Merger Suit Just Yet
- Stites & Harbison Beefs Up IP, Life Sciences Teams In Tenn.
- AbbVie Raises Shire Offer To $51B, Stoking Buyout Battle
- A Step Toward Alleviating Growing Discovery Problems
- J&J Pays Oregon $4M To Settle Hip Implant Marketing Claims
- Sanofi Sues To Block Unimark's Generic Multaq
- Novel Fights 'Patient' Claim Rehearing In Suprep Suit
- FDA Warns Gilead Of Misleading Google Search Ad
- Patients Sue NJ Hospital Network Over Meningitis Outbreak
- Watchdog Bars Ex-PwC Auditor Over $400M ArthroCare Fraud
- Pfizer Faces 3 Class Actions Over Generic Delay Scheme
- Pershing Square Reveals 6 Picks For Allergan Board
- Novartis Says Gov't Can't Prove Kickbacks Influenced Docs
- Fed. Circ. Upholds $5M Becton IP Award Despite Reversal
- Cuomo Says New Medical Marijuana Bill Delivers Balance
- Deals Rumor Mill: American Apparel, BHP Billiton, Alibaba
- Wilson Sonsini Snags PTAB Judge For IP Practice In DC
- Pfizer Critic Boosts AstraZeneca Ties Amid Talk Of New Bid
- Lawyers And Email: Ethical And Security Considerations
- Deals Rumor Mill: American Apparel, AbbVie, Lululemon
- Affymax To Pay $6.5M To End Class Action Over Anemia Drug
- J&J Gets 12 Cases Transferred Out Of NJ Pelvic Mesh MCL
- Merck Sues To Block Teva's Generic Nasonex
- Sens. Push White House To OK FDA's Lab-Test Guidance
- FTC OKs $500M Valeant-PreCision Deal With Acne Drug Sales
- Cozen O'Connor Nabs Greenberg Traurig, Sedgwick Pros In LA
- Research Firm Asks FDA To Clear Path For Generic Fosamax
- USPTO Tells Fed. Circ. Not To Rethink Clone Patent Ruling
- Sobek Fights For 'Abandoned' Nuprin Mark From Rival
- Dealmakers Q&A: Davis Polk's Michael Davis
- Novartis Beats Ala. Bone Drug Case On Expert Testimony
- 4th Circ. Per-Invoice Rule: Warnings For Gov't Contractors
- More Signs Of Telemedicine Moving Into The Mainstream
- GlaxoSmithKline Gets 219 Avandia Injury Plaintiffs Nixed
- Outcry Over Possible USPTO Pick Is Unfounded, Attys Say
- ArthroCare Execs Can't Duck Verdict In $400M Fraud Scheme
- Nexium Buyers Say Judge Shouldn't Ax Conspiracy Claims
- FDA Pressed To Strengthen Drug Trial Consent Regs
- Roche Unit To Pay Up To $1.7B For US Cancer Drugmaker
- Ex-Novartis Exec Says She Was Fired Over Study Concerns
- Kroger Eyes Bigger Online Biz In $280M Vitacost Pickup
- FTC Asks For More Info On $13.4B Zimmer-Biomet Deal
- Modifying CMS Medicare And Medicaid Incentive Programs
- Alternate Hatch-Waxman Strategies For Branded Pharma
- Novartis Wins Ruling On Duty-To-Warn Scope In Zometa Suit
- Defamation Suit Over Seeking Alpha Blog Post Thrown Out
- FDA Lays Out 4-Year Strategic Priorities Plan
- CooperVision Inks $1.2B Deal To Acquire Sauflon
- 6th Circ. Hobbles Plaintiffs In Generic-Drug Injury Suits
- Fitzpatrick Cella's Managing Partner Surfaces At Mayer Brown
- Fed. Circ. Upholds Ruling Nixing AbbVie Antibody Patents
- Valeant Puts Allergan On Defensive In $53B Buyout Fight
- Deals Rumor Mill: ConvaTec, United Biscuits, ING
- Bausch & Lomb Hits Lupin With IP Suit Over Generic Eye Drug
- GSK Wants 3rd Circ. To Toss RICO Claims In Avandia MDL
- 2014's Top Activist Plays So Far
- FDA Issues 2 Guidances On Drug Compounding
- Forest Labs Slams Ex-Sales Rep's Off-Label Namenda Suit
- Dilworth Paxson, Cryo-Cell Settle Suit Over Lost Contract
- Zurich Ordered To Cover Eisai In Off-Label FCA Suit
- Walgreen, CalPERS Lobby FDA To Drop Biosimilars Naming
- 6 Ways To Update Patent Prosecution Protocols Post-Nautilus